Skip to main content

Table 3 Change in TWSTRS scores and health utility score from baseline to visit 2 and visit 3

From: Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia

  Unadjusted Model Adjusted Modela
AboBoNT-A
LS Mean (95% CI)
OnaBoNT-A
LS Mean (95% CI)
Differenceb
(95% CI)
AboBoNT-A
LS Mean (95% CI)
OnaBoNT-A
LS Mean (95% CI)
Differenceb
(95% CI)
Change from baseline to visit 2
TWSTRS Scores
 Total −15.80 (− 17.04, − 14.57) −11.00 (− 12.94, − 9.07) −4.80 (− 7.10, − 2.50) −15.33 (− 16.53, − 14.13) −12.17 (− 14.09, − 10.24) −3.16 (− 5.49, − 0.84)
 Severity Subscale −8.49 (− 9.08, − 7.90) −6.75 (− 7.67, − 5.82) −1.74 (− 2.84, − 0.64) −8.30 (− 8.88, − 7.71) −7.21 (− 8.15, − 6.27) −1.08 (− 2.22, 0.05)
 Disability Subscale −4.56 (− 5.12, − 3.99) −2.77 (− 3.65, − 1.88) −1.79 (− 2.84, − 0.74) −4.30 (− 4.81, − 3.79) −3.39 (− 4.21, − 2.57) − 0.91 (− 1.90, 0.08)
 Pain Subscale −2.76 (− 3.20, − 2.32) −1.49 (− 2.18, − 0.80) −1.27 (− 2.09, − 0.45) − 2.67 (− 3.04, − 2.30) − 1.71 (− 2.30, − 1.12) −0.96 (− 1.68, − 0.25)
Health Utility Score 0.050 (0.046, 0.053) 0.035 (0.028, 0.041) 0.015 (0.008, 0.022) 0.048 (0.044, 0.052) 0.038 (0.032, 0.044) 0.010 (0.003, 0.017)
Change from baseline to visit 3
TWSTRS Scores
 Total −6.75 (− 7.87, −5.64) − 3.13 (− 4.87, − 1.40) −3.62 (− 5.68, − 1.56) −6.42 (− 7.52, − 5.33) − 3.94 (− 5.68, − 2.20) −2.48 (− 4.57, − 0.39)
 Severity Subscale −3.70 (− 4.21, − 3.19) −2.02 (− 2.81, − 1.22) −1.68 (− 2.63, − 0.74) −3.55 (− 4.06, − 3.05) −2.38 (− 3.18, − 1.58) −1.18 (− 2.14, − 0.22)
 Disability Subscale − 1.93 (− 2.43, − 1.42) −0.63 (− 1.42, 0.16) −1.30 (− 2.23, − 0.36) −1.78 (− 2.27, − 1.29) −1.00 (− 1.78, − 0.22) −0.78 (− 1.71, 0.16)
 Pain Subscale −1.12 (− 1.59, − 0.66) −0.48 (− 1.20, 0.24) −0.64 (− 1.50, 0.21) −1.04 (− 1.45, − 0.62) −0.70 (− 1.36, − 0.04) −0.34 (− 1.13, 0.45)
 Health Utility Score 0.021 (0.018, 0.025) 0.010 (0.004, 0.015) 0.011 (0.005, 0.018) 0.020 (0.017, 0.024) 0.012 (0.007, 0.018) 0.008 (0.001, 0.014)
  1. aFor change from baseline to visit 2, the model is adjusted for baseline score, sex, prior treatment with BoNT-A, age, presence of tremor and use of EMG; for change from baseline to visit 3, the model is adjusted for baseline score, sex, prior treatment with BoNT-A and age
  2. bDifference was calculated as follow: aboBoNT-A LS mean minus onaBoNT-A LS mean
  3. TWSTRS Toronto Western Spasmodic Torticollis Rating Scale; LS Least Square; CI Confidence Interval; SD Standard deviation; EMG electromyography; BoNT-A Botulinum Neurotoxin type A